Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous studies indicate that androgen deprivation therapy for prostate cancer is associated with diabetes and cardiovascular disease among older men. We evaluated the relationship between androgen deprivation therapy and incident diabetes and cardiovascular disease in men of all ages with prostate cancer. METHODS: We conducted an observational study of 37,443 population-based men who were diagnosed with local or regional prostate cancer in the Veterans Healthcare Administration from January 1, 2001, through December 31, 2004, with follow-up through December 31, 2005. Cox proportional hazards models were used to assess whether androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) agonists, oral antiandrogens, the combination of the two (ie, combined androgen blockade), or orchiectomy was associated with diabetes, coronary heart disease, myocardial infarction, sudden cardiac death, or stroke, after adjustment for patient and tumor characteristics. All statistical tests were two-sided. RESULTS: Overall, 14,597 (39%) of the 37,443 patients were treated with androgen deprivation therapy. Treatment with GnRH agonists was associated with statistically significantly increased risks of incident diabetes (for GnRH agonist therapy, 159.4 events per 1000 person-years vs 87.5 events for no androgen deprivation therapy, difference = 71.9, 95% confidence interval [CI] = 71.6 to 72.2; adjusted hazard ratio [aHR] = 1.28, 95% CI = 1.19 to 1.38), incident coronary heart disease (aHR = 1.19, 95% CI = 1.10 to 1.28), myocardial infarction (12.8 events per 1000 person-years for GnRH agonist therapy vs 7.3 for no androgen deprivation therapy, difference = 5.5, 95% CI = 5.4 to 5.6; aHR = 1.28, 95% CI = 1.08 to 1.52), sudden cardiac death (aHR = 1.35, 95% CI = 1.18 to 1.54), and stroke (aHR = 1.22, 95% CI = 1.10 to 1.36). Combined androgen blockade was statistically significantly associated with an increased risk of incident coronary heart disease (aHR = 1.27, 95% CI = 1.05 to 1.53), and orchiectomy was associated with coronary heart disease (aHR = 1.40, 95% CI = 1.04 to 1.87) and myocardial infarction (aHR = 2.11, 95% CI = 1.27 to 3.50). Oral antiandrogen monotherapy was not associated with any outcome studied. CONCLUSION: Androgen deprivation therapy with GnRH agonists was associated with an increased risk of diabetes and cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1980) · Health Care Management Review · doi:10.1097/00004010-198005030-00017 · Cited by 2,504
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Self-citationRisk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Self-citationAndrogen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
Roach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
Research works printed but not linked: 1
- National Committee for Quality Assurance. HEDIS 2004 Technical Specifications. Washington, DC: 2004. [Google Scholar]
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
“Although some studies indicate an increased risk of cardiovascular disease or death associated with the use of hormone therapy, the evidence is inconsistent.(104,105,107) Careful monitoring of cardiovascular risk factors is recommended for men who have received ADT.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 875
Metadata
- Authors
- Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-07
- Volume
- 102
- Issue
- 1
- Pages
- 39-46
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3107568
- OpenAlex
- W2140905531
- Cited by
- 622
- References
- 36
- Citations by year
- 2026: 8 · 2025: 21 · 2024: 28 · 2023: 23 · 2022: 26 · 2021: 35 · 2020: 37 · 2019: 43 · 2018: 38 · 2017: 44 · 2016: 42 · 2015: 56 · 2014: 51 · 2013: 35 · 2012: 62
- FWCI
- 32.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institutes of Health (5k24ca121990-07)
- National Cancer Institute (K24-CA121990)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- androgen deprivation therapy, prostate cancer, diabetes mellitus, cardiovascular disease, GnRH agonist, orchiectomy, androgen receptor antagonists, coronary artery disease, myocardial infarction, sudden cardiac death, stroke, veterans, cancer treatment side effects, older men, combined androgen blockade, adverse effects of hormone therapy, veterans' health care utilization, health care costs, health care utilization
- MeSH terms
- Administration, Oral, Aged, Androgen Antagonists, Cardiovascular Diseases, Coronary Artery Disease, Humans, Gonadotropin-Releasing Hormone, Male, Middle Aged, Myocardial Infarction, Orchiectomy, Prostatic Neoplasms, United States, Veterans, Confounding Factors, Epidemiologic, Proportional Hazards Models, Death, Sudden, Cardiac, Antineoplastic Agents, Hormonal, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. https://app.cochat.ai/papers/10.1093/jnci/djp404
- The paper
- Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010). Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djp404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.